Lates News

date
22/08/2025
According to the AI flash news, Guojin Securities released a research report on August 22, giving a buy rating to Tian Tan Biological (600161.SH). The rating reasons mainly include: 1) the continuous growth of albumin and static propylene income, with overall profit pressure on blood products; 2) the number of single blood plasma collection stations and the scale of blood collection continue to maintain a leading position in China; 3) persisting in innovation-driven, research and development work progressing smoothly. (Daily Economic News)
Latest
See all latestmore